Over the past few years we have continuously improved the organisational and technological framework for cooperation between our Pharmaceuticals and Diagnostics Divisions. Although they have different Research & Development (R&D) processes, the two divisions can share research facilities, technologies and discoveries when working together on internal projects.
This is a unique advantage that sets Roche apart from other companies. Diagnostic tools are finding increasing use in pharmaceutical research. Most importantly, close cooperation is the basis for the successful implementation of our personalised healthcare strategy.
Three Pharma R&D units
To ensure a strong flow of suitable candidate molecules into its development pipeline, Roche has built a unique innovation network of independent Pharma research and development centers.
Pharma Research and Early Development (pRED), Genentech Research and Early Development (gRED) as well as Chugai in Japan operate independently within the group. Together with more than 150 partner organisations worldwide this network promotes a diversity of research approaches, as well as enabling access to new technologies and promising drug candidates.
Our global systems enable our innovation centers to be thriving and we manage this mainly through visibility and metrics. We have set up common standards, and common understandings of the risks and opportunities in their standards.
A class-leading IT system that allows exchange of knowledge around the globe within hours of the experiment being finished leads to prediction and ultimately to better medicines. The distinguishing factor is how we manage this global group and how we allow all partners to access science and innovation in a way that suits them best.
Four Diagnostics R&D units
Within our Diagnostics Division, Professional Diagnostics, Molecular Diagnostics, Tissue Diagnostics, and Diabetes Care, we are developing a number of instruments and solutions to improve medical outcomes and make testing more efficient. We strive to further strengthen our position as the world’s leading supplier of in vitro diagnostics (IVDs). IVDs play a key role in helping doctors to detect and diagnose diseases, select appropriate treatments and monitor patient response to care. These tests are either performed in a laboratory or at the point of care on blood, tissue or other patient samples.
By offering tests that enable patients and physicians to obtain medically relevant information, we are able to improve outcomes for patients.
150+ external partnerspRED, gRED, Roche Diagnostics and Chugai operate independently within our group, forming the hubs of an innovation network that includes alliances with more than 150 outside partners, such as universities, research institutes and biotech companies. Together with our partners we turn the multiplicity of ideas into medical innovation; about one third of the current projects in Roche’s pipeline have come from these alliances.